A New Path in Cancer Care: Prof. Mike Chan’s Vision for Personalized Immunotherapy

News from Russia about a promising cancer vaccine, Enteromix, has certainly captured the attention of the global medical community. Prof. Dato’ Sri Dr. Mike Chan, a globally recognized pioneer in bioregenerative medicine and Chief Scientist of the European Wellness Biomedical Group, expressed his enthusiasm for any development that offers new hope in the fight against cancer. Prof. Chan, known for his four decades of expertise in cellular therapy and precursor stem cell research, understands that every step forward, no matter where it originates, contributes to the collective goal of improving patient outcomes worldwide. “Every new discovery, every promising trial, brings us closer to a future where cancer is no longer a death sentence,” Prof. Chan often remarks, reflecting his unwavering optimism.

The Promise of Enteromix: A Glimpse from Russia

The Russian cancer vaccine, Enteromix, has shown encouraging results in early studies, particularly against colorectal cancer, with potential for other aggressive forms like glioblastoma and melanoma. Think of it like teaching your body’s own defense system, your immune system, to spot and fight cancer cells. Enteromix uses a clever method: an mRNA platform, similar to the technology behind some COVID-19 vaccines, to give instructions to your cells. These instructions tell your body how to build tiny, harmless pieces of the cancer cells. Your immune system then learns to recognize these pieces as ‘enemies’ and prepares to attack any real cancer cells it encounters. It’s a personalized approach, meaning it’s designed for the unique genetic makeup of each patient’s tumor. Early reports suggest it can shrink tumors and slow their growth, with minimal side effects, a welcome contrast to the harshness of traditional treatments. This aligns well with Prof. Mike Chan’s philosophy of gentle yet effective therapies.

AASI: European Wellness’s Personalized Approach

While the world observes the progress of Enteromix, Prof. Mike Chan and European Wellness have been advancing their own personalized immunotherapy: Autologous Antigen-Specific Immunotherapy (AASI). Imagine AASI as a highly specialized training program for your immune system. Sometimes, when cancer is present, your immune cells might get confused or tricked by the cancer cells into not fighting. AASI takes a small sample of your own immune cells, gives them special ‘training’ outside your body to clearly identify cancer cells as ‘foes,’ and then reintroduces these super-trained cells back into your system. They then guide the rest of your immune army to attack the cancer. This approach is about precision, aiming to restore the immune system’s natural ability to recognize and eliminate cancer cells without causing widespread damage to healthy tissues. “Our goal with AASI is to empower the body’s own healing capabilities, to turn its natural defenses into a precision weapon against disease,” Prof. Chan explains, highlighting the body-centric nature of this therapy.

Key Benefits of AASI Therapy:

• Personalized Treatment: Each therapy is uniquely tailored to the individual patient’s specific biological makeup and cancer profile.
• Targets Cancer Cells Precisely: AASI aims to specifically identify and attack cancer cells, minimizing harm to healthy tissues.
• Enhances Natural Immune Response: It boosts and re-educates the body’s own defense mechanisms to fight cancer more effectively.
• Reduced Side Effects Compared to Traditional Therapies: Generally, AASI is designed to be less harsh than conventional treatments like chemotherapy, leading to a better quality of life during treatment.
• Potential for Long-Term Remission: By strengthening the immune system’s memory against cancer, AASI offers the possibility of sustained disease control and long-term remission.

Comparing Enteromix and AASI: A Visual Guide

To better understand the similarities and differences between these two innovative approaches to cancer immunotherapy, we’ve created a comprehensive comparison infographic:

Similarities and Key Distinctions

Both Enteromix and AASI share a core idea: using the body’s own immune system to fight cancer. They are both highly personalized, understanding that each patient’s cancer is unique and needs a specific response. Both aim for treatments that are more targeted and less harmful than conventional chemotherapy or radiation. They represent a move towards treatments designed specifically for each individual. Prof. Mike Chan sees these similarities as a confirmation of the direction European Wellness has been pursuing for years. “The convergence of science towards personalized, immune-driven therapies is undeniable. It validates the path we have chosen and strengthens our resolve,” he states, emphasizing the global movement towards such advanced treatments.

However, it’s important to understand their key differences. Enteromix is an mRNA-based vaccine that uses viral vectors to deliver genetic instructions, essentially teaching the immune system to recognize cancer. It’s like giving your immune system a blueprint of the enemy. AASI, on the other hand, is a cell-based therapy. It involves taking your own immune cells, specifically training them outside the body to identify cancer cells, and then reintroducing these ‘re-educated’ cells. This is more like training your soldiers directly and sending them back into battle. While Enteromix is primarily developed as a cancer vaccine, AASI has broader applications, including autoimmune diseases, where it aims to restore immune balance, and in cancer, where it aims to break the immune system’s tolerance to cancer cells. These distinct mechanisms highlight the diverse ways science is approaching immune modulation for complex diseases.

European Wellness’ Comprehensive Approach

European Wellness, under Prof. Mike Chan’s guidance, uses AASI as a key part of its comprehensive cancer care. The therapy involves taking a small amount of the patient’s blood, which is then processed to create individualized vials of AASI. These vials are then given back to the patient, usually through injections under the skin, over a period, to continuously train and strengthen the immune response against cancer. This is often combined with other supportive therapies like Hyperthermia, which uses heat to make cancer cells more vulnerable, and Immunomodulatory Therapies (like Super Transfer Factors, Thymus MO, and GCMAF) to further boost the immune system’s overall function. This multi-pronged approach ensures that the body is not only fighting the cancer directly but is also strengthened to support its own recovery.

Learn More About AASI

For those interested in learning more about the science behind AASI and its applications, you can find more information in the research paper here: https://european-wellness.eu/publications/autologous-antigen-specific-immunotherapy/